Research and Markets has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2016" report to their offering.
Fragile X Syndrome pipeline therapeutics constitutes close to 27 molecules, out of which approximately 22 molecules are developed by Companies and remaining by Universities and Institutes. Our latest report, Fragile X Syndrome - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Fragile X Syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/ls8kfq/fragile_x
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006373/en/Business Wire
Last updated on: 24/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.